SCRIMED now has a company-wide cockpit for strengths, gaps, upgrades, risks, and proof routes.

Product and services portfolio

• Weakness: Buyer conversations can still fragment if every opportunity is not forced into one offer, package, proof route, and retained boundary.
• Upgrade: Use Offerings and Service Delivery as the only path from buyer interest into paid work.
• Evidence: 10 offers, 5 packages, 8 margin controls, 7 delivery offers, and 8 work-order templates.
• Routes: /offerings, /api/offerings, /api/offerings/brief, /service-delivery, /api/service-delivery, /api/service-delivery/brief
• Packaging readiness only; no contract, PHI, certification, revenue, profit, connector, reimbursement, or clinical authority.

Revenue, margins, and enterprise business operations

• Weakness: Enterprise scale will strain margins unless every proposal is routed through price floor, scope, billing, revenue-recognition, and tax review.
• Upgrade: Make Enterprise Business Ops the mandatory gate before pricing, proposal, investment packet, renewal, or service expansion release.
• Evidence: 9 revenue capabilities, 10 margin controls, 11 team roles, 10 profit levers, and 16 blocked business claims.
• Routes: /enterprise-business-ops, /api/enterprise-business-ops, /api/enterprise-business-ops/brief, /capital-vitality, /growth-engine, /public-market-readiness
• Business-readiness material only; no legal, accounting, tax, audited financial, securities, valuation, revenue, or profit guarantee.

Client onboarding, demos, pilots, and communications

• Weakness: Manual review remains necessary before email, calendar, deck, pilot, procurement, or follow-up content leaves the company.
• Upgrade: Require a selected onboarding stage, human-reviewed template, no-PHI packet, owner, follow-up SLA, and claim guard for every buyer interaction.
• Evidence: 8 onboarding stages, 9 templates, 5 presentation packets, 8 controls, and 6 handoffs.
• Routes: /client-onboarding, /api/client-onboarding, /api/client-onboarding/brief, /demos, /pilot
• Templates and routing only; no email send, calendar creation, contract approval, procurement approval, PHI, certification, or clinical authority.

Trust, approvals, certifications, and global readiness

• Weakness: SCRIMED is not yet certified or approved for regulated healthcare claims; external review and evidence rooms remain required.
• Upgrade: Build metadata-only evidence rooms for HIPAA/BAA, SOC 2/ISO, FDA/CDS/SaMD, ONC/connectors, EU AI Act/GDPR, UK, Australia, and regional deployment packs.
• Evidence: 7 approval tracks, 5 approval agent controls, 6 certification tracks, 5 gates, 5 regional packs, and 30 required evidence items.
• Routes: /approvals-readiness, /api/approvals-readiness, /api/approvals-readiness/brief, /global-certification-readiness, /api/global-certification-readiness, /api/global-certification-readiness/brief
• Preparedness only; no HIPAA, SOC 2, HITRUST, FDA, ONC, EU AI Act, GDPR, ISO, DTAC, MHRA, or regional approval claim.

AI, API, UI, agents, and platform power

• Weakness: The platform cannot claim public API SLA, live autonomous AI, production model routing, accessibility certification, or trillion-scale equivalence.
• Upgrade: Turn Platform Power into a contract-backed operating system with model-route register, eval/red-team queue, evidence map, accessibility checklist, and cost telemetry.
• Evidence: 9 pillars, 12 controls, 7 workstreams, 7 bottlenecks, and 53 hard stops.
• Routes: /platform-power, /api/platform-power, /api/platform-power/brief, /agents, /evaluation, /trust-os
• Readiness only; no public API SLA, live autonomous AI, production model-routing approval, PHI, accessibility certification, security certification, or scale equivalence.

Health records, interoperability, and patient safety

• Weakness: Live data exchange, EHR writeback, patient matching, payer submission, diagnosis, treatment, and patient outreach remain blocked.
• Upgrade: Create customer-specific sandbox acceptance tests and source-attributed no-PHI evaluator packets before any live connector work.
• Evidence: 5 capabilities, 5 extraction stages, 6 safety checks, 5 boundary resolutions, and 20 workarounds.
• Routes: /health-records, /api/health-records, /api/health-records/brief, /api/health-records/extract, /interoperability, /clinical-authority-readiness
• No PHI, no live records, no EHR authorization, no ONC certification, no payer submission, no diagnosis, no treatment, and no live-care authorization.

24/7 review, audit, innovation, and internal research

• Weakness: Human review remains mandatory before production remediation, public claims, security coverage language, or quantum positioning.
• Upgrade: Promote continuous review into protected work queues for accuracy sampling, evidence source aging, claims guard review, security drift, regression review, and internal research gates.
• Evidence: 7 agents, 8 loops, 6 controls, 5 innovation tracks, and 4 internal research assignments.
• Routes: /continuous-review-audit, /api/continuous-review-audit, /api/continuous-review-audit/brief, /qa-evidence, /service-reliability
• Agent-assisted review only; no managed SOC/MDR, no autonomous production remediation, no public quantum claim, no certification, and no live-care authority.

Scalability, reliability, launch, and release operations

• Weakness: Enterprise traffic, buyer workspaces, support commitments, regional deployment, and reliability language must remain gated.
• Upgrade: Attach capacity assumptions, tenant owners, queue/backpressure controls, support-tier review, cost thresholds, incident/change path, and no-SLA boundary to every expansion.
• Evidence: 10 launch tracks, 6 release gates, 10 reliability controls, 9 scale domains, 10 scale controls, and 5 open scale bottlenecks.
• Routes: /launch-readiness, /release-continuity, /service-reliability, /enterprise-scalability, /api/enterprise-scalability, /api/enterprise-scalability/brief
• Readiness only; no contractual SLA, uptime guarantee, managed-service commitment, production support guarantee, PHI authority, or connector approval.

Competitive defense, security posture, and uniqueness

• Weakness: Public competitor, privacy, cyber, and security language is high-risk unless source-backed and routed through qualified review.
• Upgrade: Attach source, counter-position, proof route, no-copy boundary, and legal/privacy/cyber gate to every competitor or security claim.
• Evidence: 10 threat profiles, 6 hardening tracks, 8 legal/privacy/cyber controls, 6 deterrence layers, and 6 hard stops.
• Routes: /competitive-defense, /api/competitive-defense, /api/competitive-defense/brief, /competitive-intelligence, /trust-safety-operations
• Strategic readiness only; no legal advice, privacy approval, security certification, penetration-test authorization, partnership, protection guarantee, PHI, or live care.

Investor, clinic, partner, and capital readiness

• Weakness: Investor and clinic materials must avoid securities, solicitation, valuation, donor, tax, customer proof, reimbursement, PHI, clinical, certification, and revenue claims.
• Upgrade: Route each audience through one packet, one proof route, one blocked-claim check, one qualified-review path, and one next move.
• Evidence: 10 weakness relief tracks, 8 edge signals, 10 audience packets, 8 revenue capabilities, 9 moat signals, and 8 funding workstreams.
• Routes: /investor-audience-readiness, /api/investor-audience-readiness, /api/investor-audience-readiness/brief, /capital-vitality, /growth-engine, /pilot-deal-room
• Readiness material only; no securities offer, solicitation, investment advice, valuation assurance, donor advice, tax advice, audited financials, or revenue guarantee.

Operational efficiency, limitations, boundaries, and workarounds

• Weakness: Blocked requests can still become informal exceptions if the team does not route every issue through the workaround and boundary registers.
• Upgrade: Every blocked action gets a safe packet, owner, proof route, expiration rule, escalation trigger, and graduation gate.
• Evidence: 155 efficiency records, 9 resolution sprints, 12 limitation tracks, 8 workaround packets, and 120 boundary records.
• Routes: /operational-efficiency, /api/operational-efficiency, /api/operational-efficiency/brief, /limitations-workarounds, /boundary-resolution
• Operating control only; no approval, certification, PHI authority, clinical authority, release authority, or qualified-review waiver.

Navigation, proof access, and company clarity

• Weakness: Navigation must stay ahead of the product surface as routes multiply, or buyers and operators will struggle to find the right action.
• Upgrade: Keep Company Assessment, Product Console, Hub, Navigation Audit, Launch Readiness, Workarounds, and Service Delivery in the first decision path.
• Evidence: 164 page routes, 439 API route patterns, 76 smoke-covered HTML routes, 8 navigation groups, and 14 role journeys.
• Routes: /navigation, /api/navigation-audit, /api/navigation-audit/brief, /hub, /product
• Navigation and proof access only; route visibility does not prove protected execution, approval, certification, PHI authority, or clinical authority.

Commercial story clarity

• Weakness: The surface area can feel too large if buyers do not immediately see the three purchase paths: assessment, synthetic pilot, and enterprise operating layer.
• Improve: Keep public copy, demos, pricing, and onboarding anchored to one buyer pain, one recommended package, one proof route, and one retained boundary.
• Market signal: Competitors tend to lead with simple outcomes such as ambient documentation relief, agentic automation, payer intelligence, or incumbent platform reach.
• Proof: /offerings, /pricing, /client-onboarding, /demos
• Commercial story clarity is not a signed quote, contract approval, procurement approval, ROI guarantee, or revenue guarantee.

No-PHI proof engine

• Weakness: Customer-specific proof and live clinical evidence still require protected AAL2 release, customer authority, and qualified review.
• Improve: Package synthetic benchmark snapshots, redacted workflow findings, and buyer-safe proof packets for every pilot and diligence motion.
• Market signal: Market leaders win confidence by showing measurable workflow lift while keeping health-system risk low during evaluation.
• Proof: /pilot-demo-commercial-readiness, /pilot-evidence, /health-records, /qa-buyer-proof-release
• No-PHI proof is not PHI authority, clinical validation, live-care authorization, customer permission, or production connector approval.

Trust, boundaries, and buyer confidence

• Weakness: Boundaries can sound like limitations unless they are positioned as safer purchasing, diligence, and implementation controls.
• Improve: Make trust language buyer-facing: proof before production risk, known hard stops, accountable escalation, and human-gated release.
• Market signal: Healthcare buyers increasingly compare AI vendors on governance, evidence, security posture, and human-control pathways, not only feature lists.
• Proof: /boundary-resolution, /limitations-workarounds, /trust-center, /qa-claim-guard
• Trust positioning is not compliance certification, legal advice, security assurance, attack-proof guarantee, or managed SOC/MDR coverage.

Enterprise business discipline

• Weakness: Enterprise opportunities can still erode margin if custom requests bypass package boundaries or qualified review.
• Improve: Require a deal desk pass before every proposal, renewal, strategic partnership, investor packet, and faith-based clinic package.
• Market signal: Enterprise health-tech buyers expect vendor maturity around contracts, billing, privacy, security, support, and executive accountability.
• Proof: /enterprise-business-ops, /capital-vitality, /growth-engine, /service-delivery
• Business discipline is not accounting advice, tax advice, legal advice, audited financial reporting, securities material, or valuation assurance.

Interoperability and health-record readiness

• Weakness: Live EHR writeback, patient matching, payer submission, production connectors, and clinical data processing remain blocked.
• Improve: Add a buyer-ready sandbox simulator, connector readiness questionnaire, and patient-safety acceptance checklist to every integration conversation.
• Market signal: Incumbent EHR, RCM, and payer platforms can lean on existing integrations; SCRIMED must win by being safer, clearer, and faster to evaluate.
• Proof: /health-records, /api/health-records/extract, /interoperability, /clinical-production-readiness
• Interoperability readiness is not production connectivity, EHR writeback approval, payer submission approval, PHI authority, or live clinical care.

Agentic review and future infrastructure

• Weakness: Autonomous production remediation, public quantum claims, and live autonomous AI authority remain intentionally blocked.
• Improve: Make the external story about governed review loops while keeping quantum and advanced autonomy inside internal research gates.
• Market signal: Agentic healthcare platforms are pushing automation claims, so SCRIMED should differentiate with accountable human-gated agents and auditable loops.
• Proof: /continuous-review-audit, /platform-power, /operational-efficiency, /evaluation
• Agentic review is not live autonomous care, production remediation authority, public quantum capability, or model-routing approval.

Investor and strategic funding readiness

• Weakness: Investor-facing materials still need audited financial boundaries, customer-evidence discipline, valuation controls, and tighter KPI packaging.
• Improve: Create a diligence-ready packet map with operating metrics, proof route inventory, current safe revenue motions, and blocked-claim language.
• Market signal: Capital partners compare defensibility, proof velocity, compliance maturity, and market wedge clarity before funding healthcare AI companies.
• Proof: /investor-audience-readiness, /capital-vitality, /public-market-readiness, /pilot-deal-room
• Investor readiness is not investment advice, solicitation, securities material, valuation assurance, audited financial reporting, or revenue guarantee.

Cybersecurity, privacy, and infiltration deterrence

• Weakness: Security language remains high-risk until certification, penetration testing, vendor risk, and customer-specific reviews are externally validated.
• Improve: Maintain a security-review roadmap with protected evidence references, dependency controls, release gates, and no-certification language.
• Market signal: Large incumbents and enterprise AI vendors can sell institutional trust; SCRIMED must show discipline, proof, and transparent retained limits.
• Proof: /competitive-defense, /trust-center, /service-reliability, /release-continuity
• Cyber readiness is not security certification, penetration-test authorization, attack-proof assurance, or customer security approval.

No-PHI workflow assessment

• Buyer: Clinic, health-system department, payer operations team, or investor diligence owner
• Conversion: Assessment to synthetic pilot, protected enterprise pilot, or trust diligence package.
• Proof: /offerings, /service-delivery, /client-onboarding
• Assessment output is not clinical advice, ROI assurance, legal advice, procurement approval, or production authorization.

Synthetic pilot conversion engine

• Buyer: Executive sponsor, innovation leader, operations owner, or faith-based clinic sponsor
• Conversion: Synthetic pilot to protected proof workspace, annual operating-layer license, or managed review retainer.
• Proof: /pilot-demo-commercial-readiness, /pilots, /pilot-evidence, /qa-buyer-proof-release
• Synthetic pilot is not customer data processing, PHI authority, clinical validation, or live-care authorization.

Trust diligence fast pass

• Buyer: Security, privacy, legal, compliance, procurement, or investor diligence team
• Conversion: Diligence package to enterprise pilot, security review workbench, or readiness retainer.
• Proof: /trust-center, /approvals-readiness, /global-certification-readiness, /boundary-resolution
• Diligence support is not certification, legal advice, security assurance, BAA/DPA execution, or customer approval.

Interoperability readiness sprint

• Buyer: Health-system integration owner, EHR program lead, payer data team, or clinical operations sponsor
• Conversion: Readiness sprint to customer sandbox acceptance tests, protected connector diligence, or service-delivery work order.
• Proof: /health-records, /interoperability, /clinical-production-readiness, /service-delivery
• Readiness sprint is not production connector approval, PHI processing, payer submission, EHR mutation, or live clinical care.

24/7 governed review retainer

• Buyer: Enterprise operations, QA, compliance, clinical governance, or AI oversight leader
• Conversion: Retainer to enterprise operating-layer license, TrustOS expansion, or platform hardening sprint.
• Proof: /continuous-review-audit, /operational-efficiency, /service-reliability
• Review retainer is not managed SOC/MDR coverage, autonomous remediation, clinical review replacement, or certification.

Enterprise healthcare intelligence operating layer

• Buyer: Health-system executive, payer operations leader, platform partner, or strategic corporate investor
• Conversion: Synthetic pilot to annual license, strategic partnership, or enterprise activation program.
• Proof: /product, /platform-power, /enterprise-scalability, /enterprise-business-ops
• Operating-layer license is not EHR replacement, QHIN participation, production SLA, PHI authority, or live autonomous care.

Investor and clinic readiness package

• Buyer: Angel investor, private investor, corporate strategic, faith-based clinic investor, or mission-led clinic sponsor
• Conversion: Readiness package to paid assessment, pilot sponsorship, diligence room, or strategic partnership exploration.
• Proof: /investor-audience-readiness, /capital-vitality, /growth-engine, /market-activation
• Readiness package is not securities material, solicitation, investment advice, donor advice, tax advice, valuation assurance, or revenue guarantee.

Launch and scale readiness package

• Buyer: Founder, operator, enterprise sponsor, or customer success leader preparing a controlled launch
• Conversion: Readiness package to release support retainer, enterprise scalability work order, or protected activation plan.
• Proof: /launch-readiness, /enterprise-scalability, /service-reliability, /navigation
• Launch readiness is not public launch approval, contractual SLA, uptime guarantee, support guarantee, PHI authority, or customer go-live approval.

Compress the buyer front door

• Move: Make assessment, synthetic pilot, and enterprise operating-layer license the dominant three-path CTA across public pages.
• Success: A buyer can choose the right path in under one page without reading the whole operating map.
• Proof: /, /offerings, /pricing, /client-onboarding
• CTA clarity is not contract approval, signed quote, procurement approval, or revenue assurance.

Create a revenue proof ladder

• Move: Link each revenue builder to accepted proof artifacts, package scope, price-floor control, and blocked claims.
• Success: Every commercial conversation names one revenue builder, one proof artifact, and one retained financial boundary.
• Proof: /growth-engine, /capital-vitality, /enterprise-business-ops
• Revenue proof ladder is not ROI assurance, audited financial reporting, securities material, valuation assurance, or revenue guarantee.

Promote trust as a buying advantage

• Move: Place proof-before-risk, Claim Guard, Boundary Matrix, and human-gated release language near commercial CTAs.
• Success: Trust language directly supports demo booking, pilot conversion, procurement diligence, and investor confidence.
• Proof: /trust-center, /boundary-resolution, /limitations-workarounds, /qa-claim-guard
• Trust messaging is not certification, legal advice, security assurance, or attack-proof guarantee.

Package interoperability readiness

• Move: Create a standards map, no-PHI fixture, connector questionnaire, and patient-safety acceptance template for every integration inquiry.
• Success: Integration conversations convert into readiness sprints without implying production connector authority.
• Proof: /health-records, /interoperability, /clinical-production-readiness
• Interoperability readiness is not PHI authority, EHR writeback approval, payer submission approval, or live-care authority.

Formalize the enterprise deal desk

• Move: Add a deal-desk checklist with package, scope, price floor, margin, billing, contract, tax, accounting, and blocked-claim decisions.
• Success: No enterprise proposal leaves without margin, billing, legal, tax, accounting, and claims review.
• Proof: /enterprise-business-ops, /service-delivery, /pilot-deal-room
• Deal desk readiness is not legal advice, accounting advice, tax advice, contract approval, or profit guarantee.

Strengthen protected proof evidence

• Move: Keep protected proof as a controlled release chain with reviewer signoff, recipient control, access logs, and current-state language.
• Success: Buyer-specific evidence is shareable only through a traceable, approved, claim-guarded path.
• Proof: /qa-buyer-proof-release, /buyer-release-control-run, /pilot-workspace/access
• Protected proof readiness is not customer permission, production authorization, or public evidence release approval.

Convert continuous review into paid operations

• Move: Offer governed review retainers around evidence aging, claims drift, QA sampling, issue triage, and future research watchlists.
• Success: Continuous review becomes a scoped recurring revenue motion without autonomous production authority.
• Proof: /continuous-review-audit, /operational-efficiency, /service-reliability
• Review operations are not managed SOC/MDR, autonomous remediation, certification, or clinical review replacement.

Build the capital diligence room map

• Move: Maintain an investor packet index for company narrative, revenue builders, moat signals, current limitations, KPI posture, and qualified-review needs.
• Success: Investor conversations stay focused on evidence-backed current capabilities and clearly retained external-review boundaries.
• Proof: /investor-audience-readiness, /capital-vitality, /public-market-readiness
• Capital diligence map is not securities material, solicitation, investment advice, valuation assurance, or audited financial reporting.

External approvals and certifications are readiness-only

• Relief: Move required evidence into metadata-only evidence rooms with accountable qualified-review owners and expiration cadence.
• Proof: /approvals-readiness, /global-certification-readiness, /boundary-resolution
• No certification or regulated approval claim.

Live clinical and PHI authority remain blocked

• Relief: Use no-PHI synthetic extraction, customer sandbox acceptance tests, source-attribution checks, and protected clinical authority evidence rooms.
• Proof: /health-records, /clinical-authority-readiness, /pilot-workspace/access
• No PHI, no live data, no live care, no connector approval.

Revenue and margin claims need qualified business controls

• Relief: Gate every proposal through deal desk, margin model, finance/accounting/tax triage, Claim Guard, and protected proof release.
• Proof: /enterprise-business-ops, /capital-vitality, /qa-claim-guard
• No revenue, ROI, savings, audited financial, valuation, tax, or profit-margin guarantee.

Buyer proof release is protected and human-gated

• Relief: Require AAL2 workspace, release decision, reviewer signoff, recipient control, access-log path, and claim guard before external sharing.
• Proof: /qa-buyer-proof-release, /buyer-release-control-run, /pilot-workspace/access
• No customer-specific release, customer permission, or external proof claim without protected approval chain.

Scale language must remain bounded

• Relief: Attach capacity assumptions, support tier, SLO readiness, incident/change path, region review, cost guardrails, and no-SLA boundaries to each expansion.
• Proof: /enterprise-scalability, /service-reliability, /platform-power
• No SLA, uptime, managed-service, public API SLA, or scale-equivalence claim.

Autonomous AI and quantum positioning are internal-only

• Relief: Keep quantum and advanced autonomous remediation inside internal research queues with promotion gates, evaluation evidence, and qualified review.
• Proof: /continuous-review-audit, /platform-power, /evaluation
• No public quantum, autonomous-remediation, production model-routing, or live autonomous AI claim.

Communication and onboarding still require human send approval

• Relief: Use calendar-safe packets, no-PHI templates, follow-up owners, and presentation Claim Guard before external use.
• Proof: /client-onboarding, /demos, /qa-claim-guard
• No automatic send, invite creation, contract approval, procurement approval, or sensitive artifact sharing.

Workarounds must not become informal authority

• Relief: Assign every workaround an owner, proof route, expiration, escalation trigger, and graduation gate.
• Proof: /limitations-workarounds, /operational-efficiency, /boundary-resolution
• No workaround waives retained gates, approvals, PHI authority, certification, or qualified review.

Production tenant, SSO, and invitation activation

• Now: Use protected pilot workspace access, tenant lifecycle packets, AAL2 reviewer gates, and synthetic-only buyer rooms for evaluation without creating live customer infrastructure.
• Build: Implement signed customer tenant architecture, production SSO configuration, automated invite policy, retention/deletion controls, support owner routing, and customer authority evidence packets.
• Success: Every enterprise pilot has a tenant activation packet with owner, access model, support path, retention posture, and release gate.
• Blocked until: Customer tenant architecture, SSO policy, invite authority, retention plan, and qualified security/privacy review are complete.
• Proof: /pilot-workspace/access, /enterprise-scalability, /service-delivery
• Closure planning is not customer SSO approval, production tenancy, invite automation approval, PHI authority, or customer go-live approval.

Live EHR, payer, HIE, imaging, device, and writeback connector authority

• Now: Route every integration ask through no-PHI extraction, standards mapping, connector questionnaires, synthetic fixture validation, and patient-safety acceptance criteria.
• Build: Build customer-approved sandbox acceptance kits, connector contract tests, BAA/DPA pathway references, security review evidence, writeback prohibition controls, and go-live approval artifacts.
• Success: Every integration conversation resolves to a standards map, fixture set, safety checklist, authority gap, and customer approval dependency.
• Blocked until: Customer authority, privacy/security review, connector acceptance, clinical governance, and live-data approvals are recorded.
• Proof: /health-records, /interoperability, /clinical-production-readiness
• Connector closure is not PHI processing approval, production EHR/HIE/payer/device access, writeback approval, payer submission approval, or live-care authority.

Clinical validation and regulated-claims dossier

• Now: Keep offers positioned as no-PHI workflow intelligence, governance, documentation support, and evidence organization with explicit clinical authority hard stops.
• Build: Create intended-use dossiers, evaluation protocols, clinical reviewer matrices, external evidence references, regional classification records, and post-market monitoring plans where required.
• Success: Every clinical-adjacent capability has intended use, blocked claims, reviewer owner, evidence class, and approval dependency.
• Blocked until: Qualified clinical/regulatory/legal review and customer or regional approval evidence exist for the specific use.
• Proof: /clinical-production-readiness, /clinical-authority-readiness, /approvals-readiness
• Dossier planning is not medical advice, clinical validation, FDA/ONC approval, regional approval, diagnosis, treatment, triage, or live clinical authority.

External security, compliance, and vendor-risk evidence

• Now: Use Trust Center, Competitive Defense, Service Reliability, Launch Readiness, protected provider security review readiness, and no-certification language.
• Build: Commission qualified security review, define SOC 2/ISO/HITRUST readiness evidence rooms, maintain vendor-risk packets, dependency audit cadence, vulnerability response, and incident evidence retention.
• Success: Each procurement packet has current controls, missing external evidence, reviewer owner, review date, and prohibited certification language.
• Blocked until: External security/compliance evidence and qualified reviewer attestations exist for the specific buyer claim.
• Proof: /competitive-defense, /service-reliability, /global-certification-readiness
• Security readiness is not SOC 2, HITRUST, ISO, HIPAA, penetration-test, attack-proof, procurement, or vendor-risk approval.

Buyer proof release automation with human control

• Now: Use QA Buyer Proof Release, Buyer Release Control Runbook, AAL2 workspaces, release decisions, recipient controls, access-log reconciliation, and Claim Guard.
• Build: Add release-policy orchestration, recipient attestation workflows, packet versioning, expiry timers, reviewer dashboards, claim diffing, and evidence-room access-log reconciliation.
• Success: No buyer-specific packet can be referenced unless release chain, recipient control, claim guard, and audit evidence are complete.
• Blocked until: AAL2 reviewer signoff, release decision, recipient control, access-log path, and approved current-state language are present.
• Proof: /qa-buyer-proof-release, /buyer-release-control-run, /pilot-workspace/access
• Release automation planning is not customer permission, public proof authority, distribution approval, legal approval, or production authorization.

Support, SLA, incident, and managed-service readiness

• Now: Keep support language readiness-only and route requests through Service Reliability, Enterprise Scalability, Operational Efficiency, and Launch Readiness.
• Build: Define support tiers, incident severities, on-call rotation, escalation SLAs, customer communication templates, post-incident review packets, cost guardrails, and contract-reviewed commitments.
• Success: Every enterprise support request has a tier, cost model, incident path, communication owner, and contract-review boundary.
• Blocked until: Support tier, funding model, incident process, staffing, contract terms, and legal review are approved.
• Proof: /service-reliability, /enterprise-scalability, /launch-readiness
• Support readiness is not contractual SLA, uptime guarantee, managed-service commitment, 24/7 SOC/MDR, or production support guarantee.

Evidence vault, retention, deletion, and artifact governance

• Now: Use metadata-only references, protected packets, no raw artifact storage, no PHI, and explicit retained-source controls inside protected workspaces.
• Build: Design artifact classification, object storage policy, encryption/key ownership, deletion workflows, retention schedules, legal hold, audit export, and evidence vault access controls.
• Success: Every evidence artifact class has retention rule, deletion rule, owner, access policy, and prohibited-content check.
• Blocked until: Artifact governance, storage, retention, deletion, legal hold, and access controls are approved.
• Proof: /pilot-workspace/access, /public-market-readiness, /qa-buyer-proof-release
• Evidence vault planning is not sensitive-document storage approval, PHI storage, signed artifact storage, raw log storage, or legal-hold approval.

Model evaluation, red-team, and source-quality benchmarking

• Now: Use synthetic AgentOS evaluation, TrustOS controls, QA evidence, continuous review loops, and source-attribution checks before claims expand.
• Build: Build versioned eval suites, adversarial prompt tests, source-quality scorecards, model-route comparison, override sampling, reviewer calibration, and cost/latency telemetry.
• Success: Every agent or model route has evaluation version, failure taxonomy, reviewer calibration, source-quality metric, and blocked claim list.
• Blocked until: Evaluation protocol, reviewer threshold, source-quality score, model route owner, and escalation behavior are verified.
• Proof: /evaluation, /continuous-review-audit, /platform-power
• Eval benchmarking is not clinical validation, model-safety certification, error-free AI proof, live autonomous AI authority, or production model-routing approval.

CRM, billing, accounting, and revenue operations automation

• Now: Use Sales Operations, Attribution Analytics, Enterprise Business Ops, Deal Desk, Service Delivery work orders, and no-guarantee pricing boundaries.
• Build: Integrate CRM stage hygiene, quote-to-work-order handoff, invoice trigger tracking, collections queue, margin exception review, renewal forecasting, and accounting evidence packets.
• Success: Every opportunity has source, stage, package, price floor, billing trigger, margin status, and blocked financial claims.
• Blocked until: CRM, billing, revenue-recognition triage, tax review, and collections ownership are operationalized.
• Proof: /enterprise-business-ops, /growth-engine, /service-delivery
• Revenue operations automation is not audited financial reporting, accounting advice, tax advice, contract approval, revenue guarantee, or profit guarantee.

Investor KPI, data-room, and board metrics discipline

• Now: Use Investor Audience Readiness, Capital Vitality, Public Market Readiness, Company Assessment, and protected no-PHI metric packets.
• Build: Maintain investor data-room index, KPI definitions, cohort methodology, proof inventory, board scorecard cadence, finance methodology gates, and external-review log.
• Success: Every investor packet includes current safe metric definitions, proof source, limitation, external-review need, and prohibited claim list.
• Blocked until: KPI methodology, finance review, evidence provenance, legal review, and audience-specific boundaries are complete.
• Proof: /investor-audience-readiness, /capital-vitality, /public-market-readiness
• Investor data-room discipline is not securities material, solicitation, investment advice, valuation assurance, audited financial reporting, or revenue assurance.

Company command review

• Sequence: Review overall score and watch dimensions, Pick one now-risk and one revenue unlock, Assign owner and proof route, Record blocked claims and retained boundaries
• Success: Every major company decision references one route, one owner, one proof path, and one retained boundary.
• Proof: /company-assessment, /hub, /product, /navigation
• Operating guidance only; no launch, buyer, legal, financial, or clinical approval.

Approval and certification evidence room

• Sequence: Prioritize HIPAA/BAA, SOC 2/ISO, FDA/CDS/SaMD, ONC/connectors, EU AI Act/GDPR, and regional packs, Assign reviewer owner and evidence class, Define expiration and renewal cadence, Block public claims until review is complete
• Success: Top approval tracks have evidence owner, artifact reference policy, review status, and blocked-claim language.
• Proof: /approvals-readiness, /global-certification-readiness, /pilot-workspace/access
• Readiness only; no certification or regulatory approval.

Enterprise deal desk and margin lock

• Sequence: Select package and scope, Apply price floor and margin control, Run accounting/revenue-recognition and tax triage, Review legal, billing, and blocked claims
• Success: No proposal leaves without scope, price-floor, billing, contract, margin, and blocked-claim review.
• Proof: /enterprise-business-ops, /offerings, /service-delivery
• No accounting, tax, legal, revenue, profit, securities, or valuation assurance.

Protected buyer proof release chain

• Sequence: Use protected workspace, Attach release decision, Capture reviewer signoff, Confirm recipient and access-log path, Run Claim Guard
• Success: Buyer proof packets have AAL2 release trail, reviewer signoff, and current-state buyer language.
• Proof: /qa-buyer-proof-release, /buyer-release-control-run, /pilot-workspace/access
• No customer permission, external distribution, or protected proof claim without approval chain.

Health-record sandbox and safety evaluator

• Sequence: Choose standards and record types, Create no-PHI test fixtures, Run source attribution and patient-safety lint, Route live-data gates to authority evidence room
• Success: Every integration conversation has no-PHI fixtures, standards map, source-attribution test, and live-data approval list.
• Proof: /health-records, /api/health-records/extract, /interoperability, /clinical-authority-readiness
• No PHI, live connector, EHR writeback, payer submission, diagnosis, treatment, or care authorization.

24/7 review work queues

• Sequence: Create queue owners, Define sampling cadence, Log evidence aging and claim drift, Route production-impact changes to human approval
• Success: Accuracy sampling, source aging, claim guard, security drift, QA regression, and incident learning have owners and retained decisions.
• Proof: /continuous-review-audit, /qa-evidence, /service-reliability, /operational-efficiency
• No managed SOC/MDR, autonomous production remediation, certification, or public quantum claim.

API, UI, AI platform hardening

• Sequence: Formalize API contract register, Prioritize role-based UI command paths, Create model-route and agent approval registers, Attach eval, red-team, retrieval, and cost telemetry
• Success: Platform claims can point to contract, role, model, agent, eval, retrieval, and cost-control evidence.
• Proof: /platform-power, /agents, /evaluation, /trust-os
• No public API SLA, accessibility certification, production model routing, live autonomous AI, PHI, or scale-equivalence claim.

Enterprise scale and service reliability package

• Sequence: Attach tenant owner and capacity assumptions, Define queues and backpressure, Add incident/change path, Set support-tier and cost guardrails, Document no-SLA boundary
• Success: Scale conversations include SLO readiness, support model, incident/change route, region gate, and cost threshold.
• Proof: /enterprise-scalability, /service-reliability, /release-continuity, /launch-readiness
• No contractual SLA, uptime guarantee, managed-service commitment, production support guarantee, PHI, or connector approval.

Investor and clinic packet discipline

• Sequence: Select audience packet, Attach proof route and blocked claims, Choose next move, Route sensitive or financial language to qualified review
• Success: Audience-specific materials stay current, proof-backed, and free of securities, valuation, donor, tax, customer, PHI, or revenue overclaims.
• Proof: /investor-audience-readiness, /capital-vitality, /growth-engine, /pilot-deal-room
• No investment advice, securities material, solicitation, valuation, donor advice, tax advice, or revenue guarantee.

Navigation and public clarity release loop

• Sequence: Add high-value route to primary navigation, Add role journey and limitation control, Add smoke coverage, Update README and project-status references
• Success: Company-critical routes remain discoverable from home, hub, product, command navigation, and smoke coverage.
• Proof: /navigation, /company-assessment, /hub, /product
• Navigation route visibility is not proof of protected execution, approval, PHI authority, or clinical authority.